Abstract. Acute lymphoblastic leukemia (ALL) cells at relapse are frequently more resistant to treatment than primary clones and this may be caused by further genetic changes in the ALL cells at relapse. These acquired genomic abnormalities have not been fully characterized. To examine the additional genomic alterations of ALL at relapse, we performed single nucleotide polymorphism genomic microarry (SNP-chip) analysis on 14 ALL bone marrow samples at initial diagnosis, remission and relapse. Only two cases at initial diagnosis had a normal appearing genome by SNP-chip. All 14 cases had genomic alterations at relapse; and 10 of these had additional genomic abnormalities not present at diagnosis. Deletion of either the INK4A/ARF gene (2 cases) or the NF2 gene (2 cases) at 22q12.2 was an acquired genomic change at relapse. Loss of heterozygosity with normal copy number [uniparental disomy (UPD)] was detected in 3 cases as an additional genomic change at relapse. Interestingly, several genomic alterations, especially deletions, detected at initial diagnosis, disappeared at relapse, suggesting the ALL cells at relapse were minor clones at initial diagnosis and emerged at relapse. For several cases, trisomy at initial diagnosis changed to either UPD (2 cases) or normal appearing genome (2 cases). Further, we found disruption of PTPRD gene occurring at intron 23 as an additional genomic abnormality in one case. In summary, additional genomic changes are very common events in ALL at relapse; whether these abnormalities are associated with resistance to treatment remains to clarified in further studies.
Introduction
Pediatric acute lymphoblastic leukemia (ALL) is the most common malignant disease of children (1, 2) . Improvement of treatment for this disease has achieved disease-free survival of 80% or more at 5 years (2-4). However, one fifth of patients relapse and are often refractory to chemotherapeutic reagents (2) (3) (4) . Several clinical and genetic factors have been reported to be associated with refractoriness to treatment including high white blood cell count at diagnosis, BCR-ABL abnormality, hypodiploidy and short first complete remission (1, 2) .
Studies have suggested that chemo-sensitivity of ALL cells in vitro at initial diagnosis is a good indicator for long-term survival (5, 6) . Also, gene expression profiling of ALL cells is associated with their genetic status and chemo-sensitivity in vitro (7, 8) . Genetic abnormalities of ALL cells influence their gene expression pattern and may be associated with their chemo-sensitivity (9) .
After relapse, the leukemic cells are often refractory to standard chemotherapeutic reagents and more aggressive therapies are needed to treat this resistant disease, including hematopoietic stem cell transplantation (10, 11) . This refractoriness may be attributed to acquired additional genetic abnormalities in the leukemic cells during relapse. Genomic differences between initial and relapsed ALL have not been fully examined.
Recently, single nucleotide polymorphism genomic microarray (SNP-chip) has been developed (12, 13) . This new technique allows us to analyze genomic status of leukemic cells at very high resolution (molecular level) and allelespecific gene dosage levels (paternal and maternal alleles) can be examined (14) (15) (16) . We named this technique molecular allelokaryotyping (15, 16) . We used it on matched samples obtained at diagnosis, bone marrow remission and relapse in order to identify genomic differences between initial and relapsed ALL and to find genes associated with refractoriness of relapsed ALL cells to chemotherapeutic reagents.
Materials and methods
Patients and DNA samples. The ALL-BFM 2000 trial of the Berlin-Frankfurt-Münster (BFM) study group on treatment of childhood ALL enrolled patients from ages 1 to 18 years at diagnosis. Relapse patients were enrolled in the ALL-REZ BFM 2002 trial of the BFM study group on the treatment of relapsed ALL. Both trials were approved by the local Ethics Committee. Patient samples were selected according to availability of relapse samples. DNA of 14 cases at initial diagnosis, remission and relapse was extracted using standard techniques.
SNP-chip analysis. DNA from the 14 ALL samples at initial diagnosis and at relapse, as well as their paired normal DNA from remission samples were analyzed on Affymetrix ® GeneChip ® Human mapping 250K Nsp arrays (Affymetrix Japan, Tokyo, Japan) according to the manufacturer's protocol. Microarray data were analyzed for determination of both total and allelic-specific copy numbers using the CNAG program as previously described with minor modifications, where the status of copy numbers as well as UPD at each SNP was inferred using the algorithms based on Hidden Markov Models (14, 15) .
Quantitative genomic PCR. Quantitative genomic PCR (qPCR) was performed on the real-time PCR machine, iCycler (Bio-Rad Laboratories, Hercules, CA) using iQ SYBR-Green supermix (Bio-Rad Laboratories) according to the manufacturer's protocol. Primer sequences used for the qPCR are; NF2-S: 5'-GAG GAG CCA ATC AGT ACA TC-3', and NF2-AS: 5'-AAC ATC ATA TCT TCC ATG AA-3'. Gene dosage at the 2p allele was used as an internal control as previously reported (16) .
Results
Genomic abnormalities acquired at relapse. SNP-chip analysis using ALL samples and their matched normal controls allowed us to evaluate total and allele-specific (each parental) gene dosage as shown in Fig. 1a . For all patients, we examined their initial diagnosis, remission and relapse ALL samples by SNP-chip. We found a number of genomic abnormalities including deletions and duplications. Tables I and II list all of the abnormalities and representative results are shown in Fig. 1 . The genomic status of ALL samples was compared at initial diagnosis, remission and relapse (Table II) to identify additional genomic abnormalities at relapse.
At initial diagnosis, two cases (#655, #747) showed no abnormalities over their entire genome; and both cases developed genomic abnormalities at relapse (Table II) . Four of 14 cases had no additional genomic abnormality at relapse compared to initial diagnosis (Table I) .
Additional genomic abnormalities were noted at relapse in 10 cases (Table II) . Case #339 had no abnormality in chromosome 9p at initial diagnosis but developed a hemizygous deletion of INK4A/ARF gene on 9p at relapse (Fig. 1b and Table II) . Case #453 had a hemizygous deletion of INK4A/ARF at initial diagnosis and the matched relapsed Table I . Genomic abnormalities of pediatric ALL at initial diagnosis determined by SNP-chip analysis. 
Case, #514, #515, #562, and #615 had no additional abnormalities at relapse. Del, deletion; Dup, duplication; UPD, uniparental disomy; pter, terminal of a short arm and qter, terminal of a long arm.
sample had a homozyous deletion of this gene ( Fig. 1b and Table II) .
Two cases (#581, #794) had deletion of 22q12.2 involving NF2 as an additional genomic change at relapse (Table II and Fig. 1c ). Deletions of genes associated with development of lymphocytes and other hematopoietic cells, including EBF1, ETV6, and Evi1, also appeared for the first time at relapse (Table III) . In addition, uniparental disomy (UPD) of 16p12.3-pter was detected at relapse in case #349 (Table II and Fig. 1d ).
Disappearance of deletions at relapse. Of interest, loss of genomic materials (deletions and monosomy) detected at initial diagnosis disappeared at relapse in four cases (#407, #453, #581, #664) (Table II) . For example, while case #581 had deletion of 4q31.3 at initial diagnosis, this abnormality disappeared at relapse (Table II and Fig. 2a) . Nevertheless, other chromosomal abnormalities including del 6q, del 11p, del 11q and del 16q were present both at diagnosis and relapse (Table I , Fig. 2a and data not shown) . Case #664 had a deletion at 1p at initial diagnosis, but this region appeared normal at relapse (Table II and Fig. 2b ) while other genomic Table II . New genomic changes in matched relapsed ALL samples. 
-q12.2 -----------------------------------------------------------------------------------------------------a Hemizygous deletion of INK4A/ARF.
b Homozygous deletion of INK4A/ARF. Del, deletion; Dup, duplication; UPD, uniparental disomy; pter, terminal of a short arm and qter, terminal of a long arm. Table III . Candidate genes present in deletions found only in matched relapsed samples. abnormalities including del 6q16.1-qter were detected both at initial diagnosis and relapse (Table I and Fig. 2b) . Furthermore, case #664 also had monosomies of chromosomes 3, 4, and 20 at initial diagnosis, but had a normal appearing genome in these chromosomes at relapse (Table II, Fig. 2b ).
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Numerical chromosomal abnormalities and whole chromosome UPD. At initial diagnosis, gain of whole chromosomes including trisomy and tetrasomy, were detected in 7 cases (#339, #349, #407, #453, #562, #615, #672) and loss of whole chromosomes occurred in one case (#664) ( Table I ). In three cases (#339, #349, #664), these numerical changes disappeared at relapse in several chromosomes (Table II) . In two of these cases (#339, #349), trisomy changed to whole chromsome UPD [trisomy X to UPD chr. X (#349) and trisomy 15 changed to UPD chr. 15 (case #339)] (Table II, Fig. 3 top panel and data not shown). In two cases (#339, #349), trisomy reverted to normal genomic appearance of several chromosomes (Table II, Fig. 3 middle panel and data not shown) . In these cases, other genomic abnormalities including dup 1q21-qter (#339) were detected at both initial diagnosis and relapse. One unusual case (case #615) had UPD for each of 20 chromosomes at both initial diagnosis and relapse and had no additional genomic change at relapse (Table I) .
Disruption of PTPRD gene. Case #672 had whole chromosome 9 UPD at initial diagnosis (Table I and Fig. 4a ) and this UPD was lost at relapse. Instead of UPD, this case had duplication of 9p13-pter at relapse (Fig. 4a) . SNP-chip data defined the start-site of this duplication as intron 23 of PTPRD gene (Fig. 4b and c) , suggesting that this gene was disrupted in the ALL cells at relapse.
Discussion
Most children with ALL are cured in large part because of progressively better drugs and their mode of administration (2-4). Nevertheless, ~15-20% of the children relapse and their overall disease-free survival is poor (10, 11) . An unmet need is either to recognize these children at diagnosis and provide them alternative therapy and/or recognize new genomic therapeutic targets in the relapsed ALL cells that might hold the key for better relapse-related therapies. We previously examined the genomic abnormalities of ALL cells observed at diagnosis of 399 children and attempted to prognosticate who would relapse (16) . Except for children who had hyperdiploid ALL with normal chromosomes 17/18 or either BCR-ABL positive ALL or NUP214-ABL positive ALL, no other obvious genomic changes at diagnosis foretold who would relapse (16). Trisomy at initial diagnosis changed to either uniparental or normal disomy at relapse. ALL sample of case #339 had trisomy 13 at initial diagnosis; same region changed to UPD at chromosome 13 at relapse (top panel); same sample of ALL at initial diagnosis had trisomy 14; but at relapse, chromosome
In this study, molecular allelokaryotyping was performed on 14 relapsed pediatric ALL. We validated the SNP-chip results using real-time quantitative PCR at a number of deleted sites identified by SNP-chip (Fig. 1c and data not shown) . The real-time quantitative PCR data were congruent with the findings of SNP-chip at all sites that we examined. Furthermore, in other leukemia samples we validated the techniques using FISH (17) . These data suggested that SNP-chip analysis was reliable.
Genomic status of these ALL samples was compared with ones at initial diagnosis. Additional genetic changes were discovered at relapse in ten of 14 relapsed ALL cases. We found that acquired genomic abnormalities were common events at relapse of pediatric ALL.
Interestingly, in four cases, loss of genomic materials (deletions/monosomy) detected at initial diagnosis, disappeared at relapse. This suggests that the dominant ALL clones at diagnosis had these deletions; and other clones which did not have these changes were minor undetectable clones at diagnosis and emerged at relapsed. These minor clones may have been chemotherapy-resistant even at initial diagnosis. If the resistant clones are not detectable at initial diagnosis, predicting prognosis based on the genomic changes identified in the dominant clones will not be very successful. Defining genetic features of resistant clones and having the ability sensitively to detect these minor resistant clones at initial diagnosis, will enhance our ability to predict prognosis of patients and select therapy for these more resistant clones.
In two cases (#339, #349), trisomy 17 at initial diagnosis changed to normal appearing chromosome 17 at relapse. As mentioned above, we have found that hyperdiploid ALL with normal status of chromosome 17 have a worse prognosis than those with hyperdiploid and trisomy 17 (16, 18, 19) . Taken together, refractoriness to chemotherapeutic reagents by these cells might reflect changing trisomy 17 to normal chromosome 17.
In two cases (#339, #349), trisomy at initial diagnosis (+15, +X, respectively) changed to UPD at relapse; and as described above, trisomy at initial diagnosis also changed to normal disomy in several chromosomes at relapse. One of the three chromosomes was lost at relapse in these cases and changed to uniparental disomy or normal disomy. This may suggest that one of three chromosomes was randomly lost at relapse. UPD may not be associated with a growth advantage for cancer cells, but merely represents a random event caused by chromosomal instability. Alternatively, a duplication of either a mutation or a polymorphic site with the loss of the other normal allele may provide a drug-resistant phenotype (15, 20) .
Deletions of INK4A/ARF and NF2 were detected as additional genomic changes in two cases. Although the observation is intriguing, the number of cases that we have examined is too small to show any statistical significance. Our previous SNP-chip analysis of 399 pediatric ALL identified neither deletion of INK4A/ARF nor deletion of NF2 as an adverse factor for the prognosis (16) . We found a number of other candidate genes involved in additional genomic abnormalities in individual cases at relapse, including deletion of EBF1, ETV6, and Evi1 (Table III) . Deletions of these genes were also detected in ALL samples at initial diagnosis. To our knowledge, these abnormalities have not been associated with refractory ALL.
The commonly deleted region on 9p involves INK4A/ ARF in ALL (16, 21) ; PAX5 gene is also involved in this deletion in a number of ALL cases (16, 22) . Deletion of 9p in ALL is sometimes larger and involves PTPRD. We found disruption of the PTPRD gene at relapse, which was not detected at initial diagnosis. This may suggest that the PTPRD gene is translocated to another gene and generate a novel fusion gene (23) .
Deletion and/or rearrangement of PTPRD have been reported in other cancers including melanoma (24) , neuroblastoma (25) , cutaneous squamous cell carcinoma (26) and lung cancers (27) (28) (29) . PTPRD is localized on 9p, and this region is frequently deleted in ALL (11) . PTPRD is a receptortype tyrosine phosphatase which plays an important role in neuronal tissues (30, 31) . The gene is highly expressed in normal B-cells (30, 31) ; dysregulation of PTPRD may be associated with leukemogenesis. Mutations found in cancer cells have been classified into two types, 'driver' and 'passenger' mutations; 'driver' mutations are associated with carcinogenesis and 'passenger' mutations 'come along for the ride' but are not oncogenic (32) . Further studies are needed to clarify the importance of disruption of PTPRD and its association with leukemogenesis.
During the preparation of this study, SNP-chip analysis of relapse ALL by other investigators has been published (33) . They also found several acquired genomic abnormalities at relapse (33) .
This study defined a number of new findings which will help further analysis of genetic abnormalities in relapsed ALL. Analysis of the additional data of acquired genomic abnormalities of relapsed pediatric ALL will allow us to recognize a genomic signature strongly associated with poor prognosis which will modify our therapy and also help us to identify new therapeutic targets.
